Robert P Giugliano
Robert P Giugliano is an expert in Cardiology at Brigham and Women's Hospital (United States). As of October 2026, ScienceLeadR ranks Robert P Giugliano in the top 1% of experts worldwide for Atrial Fibrillation, Myocardial Ischemia and Arrhythmias, Cardiac. Robert P Giugliano has authored 778 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 2 of them ongoing. SLR score: 3,362 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Biochemistry - Hematology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 778
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial. PMID 42670293 — diabetes mellitus, mortality, ischemic stroke, stroke, myocardial infarction, lipoproteins, cardiovascular system, lipoproteins, hdl, cholesterol, atherosclerosis, lipoproteins, ldl, blood circulation, ischemia, apolipoproteins | Circulation Top journal | 2026 | 2 |
| Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study. PMID 42663360 — stroke, myocardial infarction, incidence, lipoproteins, cardiology, cholesterol, atherosclerosis, lipoproteins, ldl, ischemia | J Am Coll Cardiol | 2026 | 1 |
| Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial. PMID 42663056 — myocardial infarction, cardiology | Eur Heart J Top journal | 2026 | 0 |
| Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors. PMID 42556384 — anticoagulants, blood, point-of-care systems, pharmaceutical preparations, rivaroxaban, factor xa inhibitors, factor xa, thrombosis, hemostasis, sensitivity and specificity, apixaban | Thromb Haemost | 2026 | 0 |
| Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis. PMID 42549517 — anticoagulants, hemorrhage, stroke, incidence, cardiovascular system, atrial fibrillation, warfarin, blood circulation, direct-acting oral anticoagulants | Circulation Top journal | 2026 | 0 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Study of Zalunfiban in Subjects With ST elevation MI NCT04825743 — injections, safety, myocardial infarction, ambulances, st elevation myocardial infarction, therapeutics, blood platelets, injections, subcutaneous, small molecules | Phase 3 | Active not recruiting | 2021 |
| Safety and Tolerability of Abelacimab (MAA868) vs Rivaroxaban in Patients With Atrial Fibrillation NCT04755283 — safety, hemorrhage, stroke, rivaroxaban, factor xi, tablets, atrial fibrillation, coagulants, therapeutics | Phase 2 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map